
|Videos|October 11, 2016
Promising Alzheimer Antibody-Based Immunotherapy
Author(s)Bobby Lazzara, MD
Dr. Bobby Lazzara reports on a clinical trial of aducanumab, a human monoclonal antibody, in patients with prodromal or mild Alzheimer disease.
Advertisement
Aducanumab, a human monoclonal antibody, selectively targets aggregated amyloid-β. In this Medical News Minute, developed exclusively for Neurology Times, Dr. Bobby Lazzara discusses a
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Advanced Therapy with Apomorphine Pump in Parkinson’s Disease
2
SKY-0515 Demonstrates Sustained Mutant Huntingtin Lowering in Latest Phase 1/2 Study Update
3
Inside the Development of ISSCR’s New Parkinson Disease Stem Cell Program
4
Managing OFF Time in Parkinson’s Disease
5














